HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Minoru Hasegawa Selected Research

anti-scl-70 autoantibodies

1/2017RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase I Antibody-Positive Systemic Sclerosis.
9/2013Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis.
2/2013Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis.
8/2010Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
1/2010Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis.
4/2005Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
6/2004Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Minoru Hasegawa Research Topics

Disease

73Systemic Scleroderma (Systemic Sclerosis)
11/2020 - 06/2002
38Fibrosis (Cirrhosis)
01/2022 - 06/2002
15Pulmonary Fibrosis (Fibrosing Alveolitis)
05/2011 - 11/2002
14Dermatomyositis (Dermatopolymyositis)
01/2016 - 04/2003
13Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2011 - 04/2003
11Sclerosis
05/2019 - 06/2002
11Autoimmune Diseases (Autoimmune Disease)
06/2017 - 10/2005
10Neoplasms (Cancer)
01/2021 - 04/2011
9Inflammation (Inflammations)
11/2019 - 03/2002
7Pain (Aches)
04/2019 - 09/2009
7Hemorrhage
11/2012 - 03/2002
6Interstitial Lung Diseases (Interstitial Lung Disease)
10/2020 - 04/2011
5Psoriasis (Pustulosis Palmaris et Plantaris)
06/2021 - 05/2004
5Pulmonary Arterial Hypertension
10/2020 - 01/2006
5Hypersensitivity (Allergy)
02/2016 - 04/2003
5Arthus Reaction
09/2012 - 03/2002
5Contact Dermatitis (Eczema, Contact)
06/2010 - 04/2003
5Localized Scleroderma (Morphea)
10/2008 - 01/2003
5Bullous Pemphigoid (Pemphigoid)
03/2008 - 06/2006
4Disease Progression
10/2020 - 11/2013
4Hyperalgesia
08/2018 - 09/2009
4Rheumatoid Arthritis
06/2017 - 02/2007
4Bronchiolitis Obliterans Syndrome
04/2017 - 12/2012
4Bone Neoplasms (Bone Cancer)
04/2015 - 09/2009
4Myositis (Idiopathic Inflammatory Myopathies)
07/2014 - 02/2012
4Cicatrix (Scar)
09/2013 - 06/2004
4Wounds and Injuries (Trauma)
04/2013 - 09/2007
4Atopic Dermatitis (Atopic Eczema)
03/2008 - 04/2003
3Constipation
01/2021 - 01/2011
3Opioid-Induced Constipation
09/2020 - 01/2019
3Diarrhea
01/2020 - 07/2017
3Chronic Pain
04/2019 - 01/2013
3Neuralgia (Stump Neuralgia)
08/2018 - 09/2009
3Melanoma (Melanoma, Malignant)
01/2018 - 01/2012
3digital ulcers
09/2015 - 06/2009
3Lung Injury
09/2011 - 11/2002
3Diffuse Scleroderma (Progressive Systemic Sclerosis)
04/2010 - 04/2003
3Edema (Dropsy)
01/2010 - 03/2002
3Ulcer
05/2009 - 12/2005
3Connective Tissue Diseases (Connective Tissue Disease)
03/2008 - 10/2005
3Pemphigus (Pemphigus Vulgaris)
09/2007 - 06/2006
2Necrosis
02/2021 - 04/2006
2Cancer Pain
01/2021 - 01/2019
2Erythema Induratum (Bazin Disease)
09/2020 - 05/2017

Drug/Important Bio-Agent (IBA)

29AutoantibodiesIBA
11/2017 - 06/2002
25CytokinesIBA
01/2022 - 11/2002
14Immunoglobulin G (IgG)IBA
12/2012 - 12/2002
13ChemokinesIBA
10/2020 - 06/2004
13Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
07/2014 - 03/2002
12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2020 - 03/2002
11Bleomycin (Blenoxane)FDA LinkGeneric
01/2022 - 11/2002
11Interleukin-6 (Interleukin 6)IBA
01/2016 - 06/2002
11L-SelectinIBA
07/2014 - 03/2002
10EnzymesIBA
02/2021 - 04/2003
10AntibodiesIBA
11/2017 - 12/2005
9Morphine (MS Contin)FDA LinkGeneric
09/2020 - 09/2009
9AntigensIBA
01/2018 - 07/2005
7CollagenIBA
01/2018 - 04/2003
7anti-scl-70 autoantibodiesIBA
01/2017 - 06/2004
7P-SelectinIBA
01/2016 - 09/2006
6Indicators and Reagents (Reagents)IBA
08/2021 - 09/2005
6Opioid Analgesics (Opioids)IBA
01/2021 - 09/2009
6Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA
10/2020 - 06/2004
6Oxycodone (Oxycontin)FDA LinkGeneric
04/2015 - 09/2009
6ImmunosorbentsIBA
04/2015 - 04/2003
5Biomarkers (Surrogate Marker)IBA
10/2020 - 05/2011
5Analgesics (Analgesic Drugs)IBA
04/2019 - 09/2009
5Pharmaceutical PreparationsIBA
01/2019 - 12/2005
5LigandsIBA
05/2018 - 03/2008
5Immunoglobulin M (IgM)IBA
12/2012 - 01/2004
5E-SelectinIBA
08/2010 - 09/2006
4Opioid Receptors (Opioid Receptor)IBA
01/2021 - 01/2013
4naldemedineIBA
01/2021 - 01/2019
4Glycoproteins (Glycoprotein)IBA
01/2016 - 09/2007
4Proteins (Proteins, Gene)FDA Link
07/2014 - 02/2011
4Type I DNA Topoisomerases (Topoisomerase I)IBA
09/2013 - 01/2004
4Chemotactic FactorsIBA
04/2013 - 07/2003
4Antigen-Antibody Complex (Immune Complex)IBA
09/2012 - 05/2007
4Transforming Growth Factor beta (TGF-beta)IBA
01/2010 - 07/2004
3Connective Tissue Growth FactorIBA
11/2019 - 11/2012
3Monoclonal AntibodiesIBA
11/2019 - 09/2006
3Prednisolone (Predate)FDA LinkGeneric
04/2019 - 08/2004
3Messenger RNA (mRNA)IBA
01/2018 - 03/2013
3Transforming Growth Factors (Transforming Growth Factor)IBA
01/2018 - 01/2012
3AutoantigensIBA
11/2017 - 06/2002
3InterferonsIBA
11/2014 - 02/2011
3Interleukin-10 (Interleukin 10)IBA
06/2013 - 08/2008
3Immunoglobulins (Immunoglobulin)IBA
12/2012 - 05/2009
3Interleukin-17 (Interleukin 17)IBA
11/2012 - 06/2008
3Interleukin-4 (Interleukin 4)IBA
11/2012 - 06/2008
3Immunoglobulin E (IgE)IBA
09/2012 - 06/2009
3trioctyl phosphine oxide (TOPO)IBA
01/2010 - 01/2004
3Hyaluronic Acid (Hyaluronan)IBA
08/2009 - 06/2008
3B-Cell Activating FactorIBA
03/2008 - 02/2007
3SelectinsIBA
09/2007 - 09/2006
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2020 - 12/2012
2Brain Natriuretic Peptide (Natrecor)FDA Link
10/2020 - 01/2016
2Narcotic Antagonists (Opioid Antagonists)IBA
09/2020 - 01/2019

Therapy/Procedure

12Therapeutics
09/2020 - 04/2006
2Oral Administration
01/2022 - 01/2018